Sign up to access all valuation multiples
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients, with a predominance in exports. It also, through its custom synthesis, supports pharma companies for their patented products business from gram-scale requirements for clinical trials to launch, as well as late-life cycle management. Geographically, the company derives maximum revenue from Europe, and the rest from America, India, Asia (excluding India), and the Rest of the world.
1990
9.1K+
LTM Revenue $1.1B
LTM EBITDA $364M
$18.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Divi's Laboratories has a last 12-month revenue (LTM) of $1.1B and a last 12-month EBITDA of $364M.
In the most recent fiscal year, Divi's Laboratories achieved revenue of $1.1B and an EBITDA of $380M.
Divi's Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Divi's Laboratories valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| Gross Profit | $685M | XXX | $625M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $364M | XXX | $380M | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 36% | XXX | XXX | XXX |
| EBIT | $320M | XXX | $295M | XXX | XXX | XXX |
| EBIT Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| Net Profit | $267M | XXX | $251M | XXX | XXX | XXX |
| Net Margin | 24% | XXX | 23% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, Divi's Laboratories's stock price is INR 6132 (or $70).
Divi's Laboratories has current market cap of INR 1.63T (or $18.6B), and EV of INR 1.59T (or $18.2B).
See Divi's Laboratories trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $18.2B | $18.6B | XXX | XXX | XXX | XXX | $1.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, Divi's Laboratories has market cap of $18.6B and EV of $18.2B.
Divi's Laboratories's trades at 17.8x EV/Revenue multiple, and 50.9x EV/EBITDA.
Equity research analysts estimate Divi's Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Divi's Laboratories has a P/E ratio of 69.7x.
See valuation multiples for Divi's Laboratories and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $18.6B | XXX | $18.6B | XXX | XXX | XXX |
| EV (current) | $18.2B | XXX | $18.2B | XXX | XXX | XXX |
| EV/Revenue | 16.1x | XXX | 17.8x | XXX | XXX | XXX |
| EV/EBITDA | 50.1x | XXX | 50.9x | XXX | XXX | XXX |
| EV/EBIT | 57.1x | XXX | 66.7x | XXX | XXX | XXX |
| EV/Gross Profit | 26.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 69.7x | XXX | 79.7x | XXX | XXX | XXX |
| EV/FCF | 303.3x | XXX | 705.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDivi's Laboratories's last 12 month revenue growth is 15%
Divi's Laboratories's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $36K for the same period.
Divi's Laboratories's rule of 40 is 50% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Divi's Laboratories's rule of X is 71% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Divi's Laboratories and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 15% | XXX | XXX | XXX |
| Rule of 40 | 50% | XXX | 50% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 71% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $36K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Divi's Laboratories acquired XXX companies to date.
Last acquisition by Divi's Laboratories was XXXXXXXX, XXXXX XXXXX XXXXXX . Divi's Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Divi's Laboratories founded? | Divi's Laboratories was founded in 1990. |
| Where is Divi's Laboratories headquartered? | Divi's Laboratories is headquartered in India. |
| How many employees does Divi's Laboratories have? | As of today, Divi's Laboratories has 9.1K+ employees. |
| Who is the CEO of Divi's Laboratories? | Divi's Laboratories's CEO is Dr. Satchandra Kiran Divi. |
| Is Divi's Laboratories publicy listed? | Yes, Divi's Laboratories is a public company listed on NSE. |
| What is the stock symbol of Divi's Laboratories? | Divi's Laboratories trades under DIVISLAB ticker. |
| When did Divi's Laboratories go public? | Divi's Laboratories went public in 2003. |
| Who are competitors of Divi's Laboratories? | Similar companies to Divi's Laboratories include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Divi's Laboratories? | Divi's Laboratories's current market cap is $18.6B |
| What is the current revenue of Divi's Laboratories? | Divi's Laboratories's last 12 months revenue is $1.1B. |
| What is the current revenue growth of Divi's Laboratories? | Divi's Laboratories revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Divi's Laboratories? | Current revenue multiple of Divi's Laboratories is 16.1x. |
| Is Divi's Laboratories profitable? | Yes, Divi's Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Divi's Laboratories? | Divi's Laboratories's last 12 months EBITDA is $364M. |
| What is Divi's Laboratories's EBITDA margin? | Divi's Laboratories's last 12 months EBITDA margin is 32%. |
| What is the current EV/EBITDA multiple of Divi's Laboratories? | Current EBITDA multiple of Divi's Laboratories is 50.1x. |
| What is the current FCF of Divi's Laboratories? | Divi's Laboratories's last 12 months FCF is $60.1M. |
| What is Divi's Laboratories's FCF margin? | Divi's Laboratories's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Divi's Laboratories? | Current FCF multiple of Divi's Laboratories is 303.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
